Cell Therapeutics To Settle For $10.5M
In a filing with the U.S. Securities and Exchange Commission, the company said that the settlement relates to its practices regarding injectable acute promyelocytic leukemia drug Trisenox. It sold the drug to Cephalon Inc. in July 2005 for about $72 million.
The settlement with the U.S. Attorney’s office may yet change, and is pending a definitive settlement agreement,...
To view the full article, register now.